Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553654 | 0.87 | DGAT1 (0.41) | DGAT1GAAGABRA2GABRB2CYP1A2 | |
| SCHEMBL7431910 | 0.87 | DGAT1 (0.49) | DGAT1GAAGABRA2GABRB2CYP1A2 | |
| SCHEMBL13734146 | 0.84 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL15701589 | 0.84 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL20177079 | 0.84 | GABRA2 (0.41) | GAAGABRA2GABRB2CYP1A2KDM4E | |
| SCHEMBL21266229 | 0.84 | GAA (0.39) | GAAGABRA2GABRB2CYP1A2KDM4E | |
| SCHEMBL27094252 | 0.84 | DGAT1 (0.45) | DGAT1GAAGABRA2GABRB2CYP1A2 | |
| SCHEMBL13733546 | 0.84 | DGAT1 (0.61) | DGAT1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21645879 | 0.83 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL24736389 | 0.83 | DGAT1 (0.44) | DGAT1GAAGABRA2GABRB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12583838-B2 | Analogs for the treatment of disease | Insilico Medicine Hong Kong Limited (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12552778-B2 | — | — | 2026-02-17 | — | — | US | disclosed |
| EP-3941457-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4577524-A1 | METHODS OF MANUFACTURING KINASE INHIBITORS | Insilico Medicine IP Limited (HK) | 2025-07-02 | — | — | EP | disclosed |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119923387-A | Method for producing kinase inhibitors | 英矽智能科技知识产权有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543874-A1 | HERBICIDAL IMIDAZOLE-CONTAINING COMPOUNDS | Syngenta Crop Protection AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-11976069-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2024-05-07 | — | — | US | disclosed |
| EP-3941457-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3535258-B1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3829559-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020190827-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-3535258-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | DGAT1 1958/4885GAA 4732/4885GABRA2 1026/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | DGAT1 1958/4885GAA 4732/4885GABRA2 1026/4885 |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC10 | DGAT1 4019/4885GAA 410/4885GABRA2 4335/4885 |
| US-11976069-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC2 | DGAT1 3788/4885GAA 237/4885GABRA2 4257/4885 |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC10 | DGAT1 4019/4885GAA 410/4885GABRA2 4335/4885 |
| US-12552778-B2 | — | MAP4K2, MAP4K4, MAP4K1 | DGAT1 2963/4885GAA 2628/4885GABRA2 3924/4885 |
| US-12583838-B2 | Analogs for the treatment of disease | MAP4K4, MAP4K2, MAP4K5 | DGAT1 2935/4885GAA 2007/4885GABRA2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.